KR102951622B1 - 피라졸 화합물 및 그의 제조 - Google Patents

피라졸 화합물 및 그의 제조

Info

Publication number
KR102951622B1
KR102951622B1 KR1020207022279A KR20207022279A KR102951622B1 KR 102951622 B1 KR102951622 B1 KR 102951622B1 KR 1020207022279 A KR1020207022279 A KR 1020207022279A KR 20207022279 A KR20207022279 A KR 20207022279A KR 102951622 B1 KR102951622 B1 KR 102951622B1
Authority
KR
South Korea
Prior art keywords
compound
formula
methyl
alkyl
difluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207022279A
Other languages
English (en)
Korean (ko)
Other versions
KR20200118025A (ko
Inventor
수닐 샤르마
디네쉬 잔기드
프리얀카 다카
시다르트 마드왈
바라트 쿠마르
카필 쿠마르
라즈딥 아난드
아누락 자인
Original Assignee
미요카디아, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미요카디아, 인크. filed Critical 미요카디아, 인크.
Publication of KR20200118025A publication Critical patent/KR20200118025A/ko
Application granted granted Critical
Publication of KR102951622B1 publication Critical patent/KR102951622B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/72—Copper
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/08—Halides
    • B01J27/122—Halides of copper
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020207022279A 2018-02-01 2019-02-01 피라졸 화합물 및 그의 제조 Active KR102951622B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN201811003855 2018-02-01
IN201811003859 2018-02-01
IN201811003859 2018-02-01
IN201811003855 2018-02-01
IN201711042921 2018-05-30
IN201711042921 2018-05-30
PCT/IN2019/050076 WO2019150392A1 (en) 2018-02-01 2019-02-01 Pyrazole compounds and preparation thereof

Publications (2)

Publication Number Publication Date
KR20200118025A KR20200118025A (ko) 2020-10-14
KR102951622B1 true KR102951622B1 (ko) 2026-04-13

Family

ID=67478207

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207022279A Active KR102951622B1 (ko) 2018-02-01 2019-02-01 피라졸 화합물 및 그의 제조

Country Status (14)

Country Link
US (1) US11873289B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746434A4 (cg-RX-API-DMAC7.html)
JP (1) JP7402804B2 (cg-RX-API-DMAC7.html)
KR (1) KR102951622B1 (cg-RX-API-DMAC7.html)
CN (1) CN111670184B (cg-RX-API-DMAC7.html)
AU (1) AU2019213854C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020015692A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090204A1 (cg-RX-API-DMAC7.html)
IL (1) IL276410B2 (cg-RX-API-DMAC7.html)
MA (1) MA54677A (cg-RX-API-DMAC7.html)
MX (2) MX2020008151A (cg-RX-API-DMAC7.html)
MY (1) MY209060A (cg-RX-API-DMAC7.html)
SG (1) SG11202007328UA (cg-RX-API-DMAC7.html)
WO (1) WO2019150392A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54677A (fr) 2018-02-01 2021-11-17 Myokardia Inc Composés pyrazoles et leur préparation
WO2025244956A1 (en) * 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016118774A1 (en) 2015-01-22 2016-07-28 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007284386A (ja) 2006-04-18 2007-11-01 Kumiai Chem Ind Co Ltd 3−ピラゾリルフェニルスルフィド誘導体及びそれを有効成分として含有する殺虫・殺ダニ・殺線虫剤
US8324178B2 (en) 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
CN104703972B (zh) 2012-08-30 2017-05-31 拜耳农作物科学股份公司 3,5‑双(卤烷基)‑吡唑‑4‑甲酸衍生物的脱羧方法
WO2014089913A1 (zh) 2012-12-12 2014-06-19 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的并环化合物
EP3063134B1 (en) 2013-11-01 2020-08-12 Srf Limited Process for the preparation of pyrazole derivatives
EP3015458A1 (en) 2014-11-03 2016-05-04 Bayer CropScience AG Process for preparing 3,5-bis(haloalkyl)pyrazole derivatives from a,a-dihaloamines and ketimines
US11452717B2 (en) 2017-01-10 2022-09-27 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof
CN111132964A (zh) 2017-04-11 2020-05-08 欧瑞克制药公司 糖皮质激素受体调节剂
MA54677A (fr) 2018-02-01 2021-11-17 Myokardia Inc Composés pyrazoles et leur préparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016118774A1 (en) 2015-01-22 2016-07-28 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)

Also Published As

Publication number Publication date
EP3746434A4 (en) 2021-11-17
CA3090204A1 (en) 2019-08-08
IL276410B2 (en) 2024-09-01
IL276410B1 (en) 2024-05-01
MX2025003379A (es) 2025-05-02
MY209060A (en) 2025-06-18
JP2021512127A (ja) 2021-05-13
JP7402804B2 (ja) 2023-12-21
BR112020015692A2 (pt) 2020-12-08
AU2019213854C1 (en) 2023-12-14
US20210053940A1 (en) 2021-02-25
SG11202007328UA (en) 2020-08-28
AU2019213854A1 (en) 2020-09-03
CN111670184B (zh) 2026-07-10
MA54677A (fr) 2021-11-17
IL276410A (en) 2020-09-30
CN111670184A (zh) 2020-09-15
MX2020008151A (es) 2020-09-18
KR20200118025A (ko) 2020-10-14
AU2019213854B2 (en) 2023-06-15
WO2019150392A1 (en) 2019-08-08
US11873289B2 (en) 2024-01-16
EP3746434A1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
US20230219922A1 (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
CN101321522B (zh) 环氧丁醇中间体的制备方法
JP6275881B2 (ja) デュオカルマイシンのプロドラッグを製造するための改良された方法
IL301897A (en) Preparation processes of 3-FLUORO-5-(((1S,2AR)-1,3,3,4,4-PENTAFLUORO-2A-HYDROXY-2,2A,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN -7-YL)OXY)-benzonitrile
JP7402804B2 (ja) ピラゾール化合物及びその調製
JP3662761B2 (ja) フェノキシアルキルハライド誘導体の新規製造法
JP2017025014A (ja) ベンゾオキサゾール化合物の製造方法
JP2005526049A (ja) ベンゾイソキサゾールメタンスルホニルクロリドの調製及びゾニスアミドを形成するためのそのアミド化の方法
WO2022082337A1 (en) Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile
EA044890B1 (ru) Пиразольные соединения и их получение
HK40027579A (en) Pyrazole compounds and preparation thereof
CN105980354A (zh) 有害生物防治剂的制造方法及其中间体
WO2005026176A1 (ja) 3−クロロメチル-3-セフェム誘導体の製造方法
JP2001506255A (ja) チアゾール類の製造
JPH0559045A (ja) ピリジルオキシ誘導体の製造方法
JP2009249357A (ja) 1−ビニル−4−[(4−ビニルフェニル)ジスルファニル]ベンゼン誘導体
TW201936597A (zh) 製備經取代之(1h-1,2,4-三唑-1-基)醇類之方法
JP2004115476A (ja) (r)−3−ハロゲノ−2−メチルプロパノールの製造方法
KR20070090937A (ko) 2-(피라졸-1-일)피리딘 유도체
JP2020015686A (ja) トルバプタン、その塩またはそれらの溶媒和物の製造方法
KR20190016208A (ko) 신규의 설폰아마이드 중간체 및 이를 사용한 실로도신의 제조방법
JPH05140109A (ja) N‐シアノ‐n′‐(2‐ニトロキシエチル)‐3‐ピリジンカルボキシイミダミドの製造法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)